117 related articles for article (PubMed ID: 1472930)
1. Splenic lymphoma in a patient treated with interleukin-2 and dacarbazine for metastatic melanoma.
Shiloni E; Maclennan KA; Okon E; Polliack A
Leuk Lymphoma; 1992 May; 7(1-2):171-2. PubMed ID: 1472930
[No Abstract] [Full Text] [Related]
2. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
Lopez M; Carpano S; Cavaliere R; Di Lauro L; Ameglio F; Vitelli G; Frasca AM; Vici P; Pignatti F; Rosselli M
Ann Oncol; 1994 Oct; 5(8):741-6. PubMed ID: 7826907
[TBL] [Abstract][Full Text] [Related]
3. [Melanoma therapy].
Kleeberg UR
Dtsch Med Wochenschr; 1976 Jun; 101(23):904-8. PubMed ID: 773624
[No Abstract] [Full Text] [Related]
4. Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma.
Flaherty LE; Schwert R; Redman BG
J Natl Cancer Inst; 1990 Aug; 82(16):1360. PubMed ID: 2380992
[No Abstract] [Full Text] [Related]
5. Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma.
Somers SS; Reynolds JV; Guillou PJ
Clin Oncol (R Coll Radiol); 1992 Mar; 4(2):135-6. PubMed ID: 1554627
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of melanoma].
Dréno B; Wallon-Dumont G
Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
[TBL] [Abstract][Full Text] [Related]
7. The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
Punt CJ
Melanoma Res; 1998 Apr; 8(2):95-104. PubMed ID: 9610861
[TBL] [Abstract][Full Text] [Related]
8. The skin: an immunoreactive target organ during interleukin-2 administration?
Dummer R; Miller K; Eilles C; Burg G
Dermatologica; 1991; 183(2):95-9. PubMed ID: 1743379
[TBL] [Abstract][Full Text] [Related]
9. [Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].
Hauschild A
Hautarzt; 1996 Jan; 47(1):67-8. PubMed ID: 8835010
[No Abstract] [Full Text] [Related]
10. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
11. Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo.
Nishitani N; Bito T; Ikeda T; Tokura Y; Nishigori C
J Dermatol; 2010 Aug; 37(8):770-2. PubMed ID: 20649729
[No Abstract] [Full Text] [Related]
12. Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma.
Chun ES; Demos TC; Gaynor ER
J Comput Assist Tomogr; 1997; 21(4):674-6. PubMed ID: 9216783
[TBL] [Abstract][Full Text] [Related]
13. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
Merimsky O; Inbar M; Shiloni E; Ron I; Chaitchik S
Mol Biother; 1990 Dec; 2(4):208-10. PubMed ID: 2288720
[TBL] [Abstract][Full Text] [Related]
16. Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Guenova E; Lichte V; Hoetzenecker W; Woelbing F; Moehrle M; Roecken M; Schaller M
Melanoma Res; 2009 Aug; 19(4):271-3. PubMed ID: 19550360
[TBL] [Abstract][Full Text] [Related]
17. [Systemic therapy of metastatic malignant melanoma].
Stahel RA; Martz G
Schweiz Rundsch Med Prax; 1988 Apr; 77(17):459-62. PubMed ID: 3259710
[No Abstract] [Full Text] [Related]
18. [Clinical trial of local immunomodulation with DNCB in cases of advanced melanoma of the skin].
Budzanowska E; Pawlicki M
Przegl Dermatol; 1988; 75(1):29-34. PubMed ID: 3290999
[No Abstract] [Full Text] [Related]
19. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract][Full Text] [Related]
20. [Modern trends in the therapy of malignant melanoblastoma (author's transl)].
Richter J; Duchková H; Rus J; Kubíková M
Cas Lek Cesk; 1976 Nov; 115(45):1385-9. PubMed ID: 1000546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
